Abstract | PURPOSE: METHODS: A retrospective cohort study on a consecutive series of ranibizumab intravitreal injections for epiretinal membranes was performed. Four cases were identified by reviewing a claims database linked to electronic medical records. All patients received a total of three 0.05 mg/0.05 ml ranibizumab intravitreal injections at a monthly interval. The primary outcome measure was the final best-corrected visual acuity (BCVA) at the end of the injection series, and the final central macular thickness (CMT). RESULTS: All four patients completed 3 months follow-up after the last ranibizumab injection. The mean baseline CMT was 509 microns (SD = 111). A trend was noticed for reduction in CMT (Δ = 41 microns) P = 0.08. Three patients improved by one line in their BCVA. The remaining patient maintained the same BCVA. No complications were noted. CONCLUSION:
|
Authors | Marwan A Abouammoh, Michel J Belliveau, David R P Almeida, Jeffrey S Gale, Sanjay Sharma |
Journal | Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
(Saudi J Ophthalmol)
Vol. 27
Issue 2
Pg. 79-82
(Apr 2013)
ISSN: 1319-4534 [Print] India |
PMID | 24227966
(Publication Type: Journal Article)
|